Cadila Healthcare Limited

economics project on Cadila and its financial/ratio analysis

1. Manshakaur Dhillon - 91 Darshit Ajmera - 92 Mayura Joshi - 93 Swati Agarwal - 94 Mohid Cutterwala - 95 Cadila Healthcare Limited

2. Indian Pharma Industry 4/9/2013 MET’s ICS Economics Growing at about 8% to 9% annually. It meets around 70% of the country's demand. Reasons for rising demand for pharma products : Low drug penetration Rising middle-class & disposable income Increased government & private spending Increasing medical insurance penetration etc. 

3. 4/9/2013 MET’s ICS Economics Globally, India ranks 3 rd in terms of manufacturing pharma products by volume. McKinsey & Company’s report, predicted that the Indian pharmaceuticals market will grow to US$55 billion in 2020 With aggressive growth strategies being implemented, it has further potential to reach US$70 billion by 2020

4. Cadila healthcare - Overview 4/9/2013 MET’s ICS Economics Established in 1952 - Headquartered in Ahmedabad, Gujarat. Ranked 5th in the domestic market. Company evolved over the next four decades into one of India's renowned pharmaceutical companies. Cadila Healthcare became the Patel family's holding company in 1995 after the Modi families split

5. 4/9/2013 MET’s ICS Economics IPO on Bombay Stock Exchange in 2000. Cadila manufactures a range of products:- Formulations of active pharmaceutical ingredients (API) Intermediates Biologicals Animal healthcare products Consumer wellness products Cadila has a global presence.

6. 4/9/2013 MET’s ICS Economics The group now has 81 patents and around 186 more pending. The product will have estimated sales of USD 3 billion in 2015. Cadila healthcare reported 1.33 % increase in net profit as on 7 th August 2013 for the quarter ended June 30, 2013

7. 4/9/2013 MET’s ICS Economics In 2012-13,Cadila’s R&D expenditure as a percentage of turnover was 12.67 % It has a 950 member strong R&D team The company undertakes R&D activities in - Generics formulations New molecular entities Novel drug delivery systems Biologics Research & Development

8. 4/9/2013 MET’s ICS Economics Cadila has a pipeline of 15 biosimilars (officially approved subsequent versions of innovative biopharmaceutical products) Cadila commissioned a manufacturing facility near Ahmedabad, which is catering to the global biosimilars business

9. R&D Expenditure break-up in 2012-13 (in crores ) 4/9/2013 MET’s ICS Economics

10. Break up of R&D team 4/9/2013 MET’s ICS Economics

11. 4/9/2013 MET’s ICS Economics Cadila is focusing on new drug discovery research in line with its long-term vision to become a g lobal research-driven company by 2020 . It has built the state-of-the-art Zydus Research Center (ZRC) with a dedicated research team of over 950 research professionals.

12. 4/9/2013 MET’s ICS Economics Biologics - a key long-term opportunity given the intense competition in the global developed generics markets and the high entry barriers in the ‘Biologics’ field leading to lesser competition. Vaccines – another niche opportunity. The first achievement - the DCGI nod to start clinical trials of the vaccine for H1N1 Flu. It is the first Indian company to get such approval.

13. M a jor coll a bor a tions in p a st few ye a rs . 4/9/2013 MET’s ICS Economics Zydus - Hospira JV in yr 2009 Zydus - Abbott Laboratories alliance in yr 2010 Bayer Zydus Pharma in yr 2011 Zydus - IDRI in yr 2013

14. CSR Initiatives 4/9/2013 MET’s ICS Economics Ramanbhai Foundation : The Zydus School for Excellence Outreach programmes Theme - Colours of Life (to spread joy and happiness to the community) Tree plantation drive - ‘Each one, plant one’ It extends support during times of natural calamities. Social and Corporate Governance Award

15. 4/9/2013 MET’s ICS Economics Shareholding pattern

16. 4/9/2013 MET’s ICS Economics Break-up of revenue

17. 4/9/2013 MET’s ICS Economics Revenue from domestic business Revenue from export business

18. 4/9/2013 MET’s ICS Economics Equity Dividend%

19. 4/9/2013 MET’s ICS Economics

20. 4/9/2013 MET’s ICS Economics

21. 4/9/2013 MET’s ICS Economics

22. 4/9/2013 MET’s ICS Economics

23. Future Prospects 4/9/2013 MET’s ICS Economics Beyond the Billion VICA PRISM 15 markets India`s first Chemical Novel

24. Conclusion 4/9/2013 MET’s ICS Economics